Fri, April 27, 2018

Matthew Harrison Maintained (VRTX) at Buy with Increased Target to $207 on, Apr 27th, 2018

Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $200 to $207 on, Apr 27th, 2018.

Matthew has made no other calls on VRTX in the last 4 months.



There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Matthew


  • Jason McCarthy of "Maxim Group" Maintained at Strong Buy with Increased Target to $200 on, Monday, March 5th, 2018
  • Liisa Bayko of "JMP Securities" Maintained at Buy with Increased Target to $211 on, Tuesday, February 13th, 2018
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $196 on, Tuesday, February 13th, 2018
  • Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $191 on, Thursday, February 1st, 2018
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $200 on, Thursday, February 1st, 2018
  • Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $197 on, Thursday, February 1st, 2018